These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 2527223

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of teicoplanin in burn patients.
    Potel G, Moutet J, Bernareggi A, Le Normand Y, Meigner M, Baron D.
    Scand J Infect Dis Suppl; 1990; 72():29-34. PubMed ID: 2151064
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The pharmacokinetics of teicoplanin in varying degrees of renal function.
    Lam YW, Kapusnik-Uner JE, Sachdeva M, Hackbarth C, Gambertoglio JG, Sande MA.
    Clin Pharmacol Ther; 1990 May; 47(5):655-61. PubMed ID: 2140543
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers.
    Smithers JA, Kulmala HK, Thompson GA, Antony KK, Lewis EW, Ruberg SJ, Kenny MT, Dulworth JK, Brackman MA.
    Antimicrob Agents Chemother; 1992 Jan; 36(1):115-20. PubMed ID: 1534211
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses.
    Del Favero A, Patoia L, Rosina R, Buniva G, Danese A, Bernareggi A, Molini E, Cavenaghi L.
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2551-7. PubMed ID: 1839759
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment.
    Domart Y, Pierre C, Clair B, Garaud JJ, Regnier B, Gibert C.
    Antimicrob Agents Chemother; 1987 Oct; 31(10):1600-4. PubMed ID: 2963586
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of teicoplanin.
    Ripa S, Ferrante L, Mignini F, Falcioni E.
    Chemotherapy; 1988 Oct; 34(3):178-84. PubMed ID: 2970949
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humans.
    Antony KK, Lewis EW, Kenny MT, Dulworth JK, Brackman MB, Kuzma R, Yuh L, Eller MG, Thompson GA.
    J Pharm Sci; 1991 Jun; 80(6):605-7. PubMed ID: 1834827
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.